Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Prognostic and Predictive Role of PD-L1 Expression in Stage III Non-small Cell Lung Cancer Treated With Definitive Chemoradiation and Adjuvant Durvalumab

International Journal of Radiation Oncology*Biology*Physics(2022)10.1016/j.ijrobp.2022.03.015Source: DataRank Database

Prognostic and Predictive Role of PD-L1 Expression in Stage III Non-small Cell Lung Cancer Treated With Definitive Chemoradiation and Adjuvant Durvalumab is a research paper published in International Journal of Radiation Oncology*Biology*Physics (2022). On theSindex it has a DataRank of 0. It has been cited 21 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access21 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (7 grants)Impact (FWCI 1.49)OA: greenTopics (28)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (8)

K. Nathan Sankar ORCID,Garth W. Strohbehn ORCID,Lili Zhao ORCID,Victoria Daniel,David J. Elliott ORCID

Live enrichment

PubMed:35450753 PMC:PMC9246927 OpenAlex:https://openalex.org/W4224286273

Melanoma Research Alliance

Grant: MRA 689853

National Cancer Institute

Grant: CA252010

BLRD VA

Grant: I01 BX005267

NCI NIH HHS

Grant: R21 CA252010

NCI NIH HHS

Grant: R01 CA276217

U.S. Department of Veterans Affairs

NIH

FWCI

1.49

Citation Percentile

0.8%

Citation Trend

2022

2023

2024

2025

2026

greenLicense: http://www.elsevier.com/open-access/userlicense/1.0/

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/9246927

publisherhttps://api.elsevier.com/content/article/PII:S0360301622002486?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0360301622002486?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.ijrobp.2022.03.015

Fields of Study

Cancer Immunotherapy and BiomarkersLung Cancer Diagnosis and TreatmentLung Cancer Research StudiesB7-H1 AntigenCarcinoma, Non-Small-Cell LungChemoradiotherapyHumansLung NeoplasmsPrognosis

MeSH Terms

Carcinoma, Non-Small-Cell LungHumansLung NeoplasmsPrognosisChemoradiotherapyB7-H1 Antigen

Keywords

DurvalumabMedicineHazard ratioInternal medicineOncologyLung cancerStage (stratigraphy)AdjuvantConfidence intervalCancerImmunotherapyNivolumabBiology

Sustainable Development Goals

SDG 0: Good health and well-being